Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
K Sugano - Therapeutic advances in gastroenterology, 2018 - journals.sagepub.com
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
K Sugano - Therapeutic Advances in Gastroenterology, 2018 - cir.nii.ac.jp
抄録< jats: p> Potassium-competitive acid blocker (P-CAB) is a class of drug that
competitively blocks the potassium-binding site of H< jats: sup>+</jats: sup>, K< jats …
competitively blocks the potassium-binding site of H< jats: sup>+</jats: sup>, K< jats …
[HTML][HTML] Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to …
K Sugano - Therapeutic Advances in Gastroenterology, 2018 - ncbi.nlm.nih.gov
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
K Sugano - Therapeutic Advances in Gastroenterology, 2018 - europepmc.org
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
K Sugano - Therapeutic Advances in Gastroenterology, 2018 - search.ebscohost.com
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H< sup>+, K< sup>+-adenosine triphosphate (ATP) ase. Although …
potassium-binding site of H< sup>+, K< sup>+-adenosine triphosphate (ATP) ase. Although …
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
K Sugano - Therapeutic advances in gastroenterology, 2018 - pubmed.ncbi.nlm.nih.gov
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
K Sugano - Therapeutic Advances in Gastroenterology, 2018 - europepmc.org
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …